Evidence map›Paper›PMID 41801430›Full record

ArticleCancer immunology, immunotherapy : CII2026

A two-step scoring model incorporating visceral-to-subcutaneous fat ratio and systemic immunoinflammatory index for predicting cytokine release syndrome severity in patients with gastric cancer receiving Claudin18.2-targeted CAR-T cell therapy.

Meng He, Lian Liu, Zifan Chen, Yiting Liu, Chang Liu, Mingyang Ma, Jiarui Li, Bin Dong, Jifang Gong, Lin Shen and 2 more

Abstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Meng He *Department of Radiology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Lian Liu *Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, 52 Fucheng Road, Beijing, 100142, China.
Zifan Chen *Center for Data Science, Peking University, Beijing, China.
Yiting LiuDepartment of Radiology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Chang LiuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Early Drug Development Centre, Peking University Cancer Hospital and Institute, 52 Fucheng Road, Beijing, 100142, China.
Mingyang MaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, 52 Fucheng Road, Beijing, 100142, China.
Jiarui LiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, 52 Fucheng Road, Beijing, 100142, China.
Bin DongBeijing International Center for Mathematical Research (BICMR), Peking University, Beijing, China.
Jifang GongState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Lin ShenState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, China. shenlin@bjmu.edu.cn.
Lei TangDepartment of Radiology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, 100142, China. tanglei@pku.edu.cn.
Changsong QiState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Early Drug Development Centre, Peking University Cancer Hospital and Institute, Beijing, 100142, China. changsongqi@bjmu.edu.cn.

Funding

Beijing Hospitals Authority Youth Programme QMS20201101National Natural Science Foundation of China U24A20759, 82441018, 12090022, 92259302, 82373438Noncommunicable Chronic Diseases-National Science and Technology Major Project 2024ZD0520600Science Foundation of Peking University Cancer Hospital JC202301, JC202303, JC202406
6 · The paper itself

Abstract

Cytokine release syndrome (CRS) greatly impacts survival in patients who undergo chimeric antigen receptor (CAR)-T cell therapy, and the identification of its determinants is still challenging. We analysed the impact of systemic immunoinflammatory index (SII) and body composition parameters derived from CT images on the severity of CRS in 45 patients with advanced gastric cancer treated with CLDN18.2-targeted CAR-T cells. The waist circumference, skeletal muscle index (SMI), skeletal muscle density (SMD), subcutaneous fat area (SFA), visceral fat area (VFA) and VFA-to-SFA ratio (VSR) on baseline CT were automatically segmented and calculated using a deep learning-based tool. The relationship between SII, body composition, and CRS severity was investigated by using ROC analysis, univariate and multivariate binary logistic regression. There were no significant differences in SMI, SMD, SFA and waist circumference between patients with CRS grade 1 and 2. CRS grade 2 patients exhibited significantly higher VSR and SII than patients with CRS grade 1 (P = 0.003 and 0.012, respectively). ROC analysis showed that the AUCs of VSR and SII for predicting CRS grade were 0.762 (0.620-0.905) and 0.721 (0.563-0.879), respectively. Logistic regression analysis demonstrated that SII > 553 × 10

Indexed as

ClaudinsCytokine Release SyndromeImmunotherapy, AdoptiveIntra-Abdominal FatStomach NeoplasmsSubcutaneous FatAdultAgedFemaleHumansMaleMiddle AgedPrognosisReceptors, Chimeric AntigenSeverity of Illness IndexClaudinsReceptors, Chimeric AntigenBody composition parametersChimeric antigen receptor-T cell therapyCytokine release syndromeNutritional status

Identifiers

PMID41801430
PMCPMC12972397

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.